Ab0005 hla Class Ii Confers Resistance or Susceptibility to Hidradenitis Suppurativa in a Caucasian Spanish Population (Northern Spain)

Abstract

Background:Hidradenitis suppurativa (HS) is a chronic inflammatory cutaneous disease affecting terminal hair follicles in apocrine glands bearing skin. The pathogenesis of HS remains unknown, although increasing evidence suggests that the immune system plays an important role. To date, two previous studies, did not find any association betweenHLAand HS.Objectives:Our aim was to analyze the association of HLA class II with HS in a Caucasian population from Cantabria (northern Spain).Methods:In this study we analyzed theHLA-A, -B, -C, DRB1, -DQA1 and –DQB1allele distribution in 106 HS patients and 262 age- and sex-matched controls from a Caucasian population of Cantabria (northern Spain).Results:HLA-A*29 andB*50 were significantly more frequent in HS patients andA*30 andB*37 in controls, but these associations disappeared after correction. On the other hand,DRB1*07,DQA1*02 andDQB1*02 were significantly more frequent in controls (p0.026,p0.0012 andp0.0005 respectively), and theHLAalleleDQB1*03:01 was significantly more frequent in HS patients (p0.00007) all of them after Bonferroni correction. Furthermore, theDRB1*07;DQA1*02;DQB1*02 haplotype was significantly more frequent in controls (p0.0005).Conclusion:This is the first study showing an association of HLA-class II with HS. Our results suggest that HLA-II alleles (DRB1*07,DQA1*02,DQB1*02 andDQB1*03:01) and theDRB1*07~DQA1*02~DQB1*02 haplotype could influence on resistance or susceptibility to HS.References:[1]González-López MA. J Am Acad Dermatol. 2016; Aug;75(2):329-35.[2]González-López MA. PLoS One. 2018 Jan 4;13(1).[3]Vilanova I. J Eur Acad Dermatol Venereol. 2018 May;32(5):820-824.[4]Durán-Vian C, et al. J Eur Acad Dermatol Venereol. 2019 Nov;33(11):2131-2136.Disclosure of Interests:Monica Calderón-Goercke: None declared, J. Gonzalo Ocejo-Vinyals: None declared, Miguel A González-Gay Grant/research support from: Pfizer, Abbvie, MSD, Speakers bureau: Pfizer, Abbvie, MSD, Marcelo A. Fernández-Viña: None declared, Juan Cantos-Mansilla: None declared, Iosune Vilanova: None declared, Ricardo Blanco Grant/research support from: AbbVie, MSD, and Roche, Speakers bureau: AbbVie, Pfizer, Roche, Bristol-Myers, Janssen, and MSD, Marcos González-López: None declared